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ABSTRACT
Background: The aim of this prospective randomized study was to evalu-
ate the effect of waiting time (WT) on health-related quality of life
(HRQoL), knee pain and physical function, and the use and costs of
medication of patients awaiting total knee replacement.
Methods: When placed on the waiting list, 438 patients were randomized
into a short waiting time (SWT  3 months) or a nonﬁxed waiting time
(NFWT > 3 months) group. HRQoL was measured by the 15D, and pain
and physical function by modiﬁed Knee Society Clinical Rating System at
baseline, admission, and 3 and 12 months postoperatively. The costs of
medication due to osteoarthritis were calculated at the same measurement
points. All analyses were performed using the intention-to-treat
principle.
Results: The mean WT was 94 and 239 days in the SWT and NFWT
groups, respectively. Apart from higher weekly cost of medication in the
SWT group at admission and better HRQoL in the NFWT group 1 year
postoperatively, there were no statistically signiﬁcant differences between
the groups in other outcomes during the follow-up.
Conclusion: Those in the SWT group had higher weekly costs of medica-
tion at admission, and reached better HRQoL 3 months earlier than those
in the NFWT group, but the latter had better HRQoL after operation.
Otherwise, the length of WT was not associated with different health and
HRQoL outcomes in the groups.
Keywords: cost, health-related quality of life, osteoarthritis, randomized
clinical trial, waiting lists.
Introduction
Osteoarthritis (OA) is the most common cause of musculoskeletal
disability and pain in the world. In Finland, 6% of men and 8% of
women over the age of 30 years suffer from clinically diagnosed
knee OA. The incidence of radiological and clinical knee arthritis
increased with age both in men and women [1]. During 2004, a
total of 5905 total knee replacements (TKRs) were performed
with the median waiting time (WT) to surgery being 209 days.
According to statistics, the number of TKRs increased to 9033 and
median WT decreased to 149 in 2006 [2]. In 2005, the Finnish
Social Insurance Institution paid EUR 85 million in drug reim-
bursements to 990,637 patients with musculoskeletal diseases,
with the mean cost being EUR 86 per year [3].
Patients with OA experience increasing pain and progressive
loss of physical function, walking, and stair climbing [4–8].
Earlier studies have established that arthritis causes difﬁculties in
participating in daily activities, which in turn affect quality of life
[9–12]. Physiotherapy and pharmacological treatment (paraceta-
mol and nonsteroidal anti-inﬂammatory drugs) are used to
reduce the symptoms, namely joint pain, stiffness, and swelling.
But, if OA pain is not otherwise manageable, patients’ ability to
manage everyday tasks is essentially compromised because of
OA, or if there is signiﬁcant restriction of motion, or a joint
malposition, a TKR should be performed [1].
In many Western countries, WTs for TKR are long [13]. In
discussion on health policy in Finland, long WTs are regarded as
a major problem for several reasons. They are claimed to violate
the principle of equal access to treatment, which is a key perfor-
mance indicator of health care in Finland. They are also claimed
to result in extra suffering, extra cost to the patients and the
society, and poorer treatment outcomes. Nevertheless, it is
unclear to what extent these claims are true as there is little solid
evidence to substantiate them.
To our knowledge, no prior studies have looked at the effect
of WT on health-related quality of life (HRQoL) and the costs of
disease-speciﬁc medication (DSM) among knee replacement
patients in a randomized study design. The aim of this prospec-
tive randomized study was to identify the effects of WT on health
and quality-of-life outcomes, and the use and costs of disease-
speciﬁc medication among two different patient groups: a short
WT group (3 months) and a nonﬁxed WT group (>3 months).
The question of whether the length of WT for TKR affects the




Between August 2002 and November 2003, 555 TKR patients in
three Finnish hospitals were invited to participate in the study:
two of the hospitals (the Surgical Hospital and Jorvi Hospital)
are part of the Helsinki University Central Hospital, while the
third is the Coxa Hospital for Joint Replacement. Patients were
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recruited into the study through contact with orthopedic and
practice staff.
The key inclusion criteria were the need for a primary TKR
due to OA of the knee joint as evaluated by the hospital surgeon,
the patient was adult (aged 16 or older) and placed on the
waiting list in a research hospital, and the patient was willing and
mentally able to participate in the study. The key exclusion
criteria were patients with rheumatoid arthritis, fractures, and
congenital hemophilia or congenital deformities.
Randomization
After being placed on the hospital waiting list, the patients were
randomly assigned to one of two groups: 1) a short waiting time
(hereafter SWT) with a maximum 3 months wait; or 2) a non-
ﬁxed waiting time (hereafter NFWT) with surgery performed
according to the hospital’s routine procedure, with the waiting
period measured from the date the patient was added to the
waiting list to the date of admission for surgery. The number of
patients placed on the waiting list varied from 1 month to
another, being speciﬁc to each hospital. Therefore, no advance
estimate could be made of the number of patients to be placed on
the list.
The patients were recruited into the study in three (in one
hospital) or four recruitment periods (in two hospitals), each
period lasting 3 months to avoid the WT for the SWT group
exceeding 3 months. Patients randomized into the SWT group
were operated within 2 weeks after the end of each recruitment
period, and only half of the hospital’s 1 month surgical capacity
could be allocated to the SWT group, so the number of SWTs
was restricted and determined speciﬁcally for each hospital. The
size of the NFWT group was not restricted to ensure that all
eligible patients placed on the waiting list had an opportunity to
be recruited into the study. The two patient groups therefore
differed in size.
Computer-generated randomization sequences were pro-
duced by the National Research and Development Centre for
Welfare and Health, and supplied to the hospitals using consecu-
tively numbered and sealed opaque envelopes. The patient’s
named nurse assigned participants to their groups after the deci-
sion for surgery had been made. The randomization envelopes
contained information on whether the patient belonged to the
SWT or NFWT group. Surgeons were blinded to patient alloca-
tion. For ethical reasons, double-blinding was not possible.
The patients completed a self-administered questionnaire
when placed on the waiting list, at admission, and at 3 and 12
months postoperatively. The questionnaires were either distrib-
uted to the patients at the hospital or in some cases mailed to
patients, as happened with one hospital for the third and fourth
questionnaires. All questionnaires were returned by prepaid post.
Common guidelines for administering the questionnaires were
provided in each hospital. The patients completed a sociodemo-
graphic form, reported their medication and comorbidities as
diagnosed by a medical doctor, and completed the disease-
speciﬁc modiﬁed Knee Society Clinical Rating System (KS) and a
separate questionnaire for HRQoL. Each patient provided
informed consent. The study was approved by the Helsinki Uni-
versity Central Hospital Surgery Ethics Committee.
Measurement Instruments
HRQoL was measured by the generic 15D instrument. The 15D
is composed of 15 dimensions: moving, vision, hearing, breath-
ing, sleeping, eating, speech, eliminating, vitality, usual activities,
mental function, discomfort and symptoms, depression, distress,
and sexual activity. Each dimension has ﬁve ordinal levels to
choose from. The 15D can be used as a proﬁle measure or to give
a single index score by means of population-based preference
weights. The index score (15D score) ranges from 0 (dead) to 1
(completely healthy) [14]. Completing the 15D questionnaire
takes 5 to 10 min, and it describes the HRQoL of the respondent
at present. A difference of >|0.03| in the 15D score is clinically
important in the sense that on average people can feel the differ-
ence [15]. The 15D was chosen for three main reasons: 1) it has
been used successfully in earlier studies dealing with knee
replacement and facilitates thus a comparison to the presurgery
scores in these studies; 2) earlier research has shown that in most
of the important properties (reliability, content validity, sensitiv-
ity in terms of discriminatory power, and responsiveness to
change), the 15D compares at least equally with other similar
instruments that produce a valuation-based single index number
[16,17]; and 3) recent research has since conﬁrmed that espe-
cially in the rehabilitation of musculoskeletal disorders, the 15D
was at least as responsive as the SF-6D, if not better. These two
instruments were anyway the most responsive ones [18].
By using the mean 15D scores from each measurement point
and assuming a linear change in the scores between the measure-
ment points, we also estimated the possible gain in quality-
adjusted life-years (QALY gain) for both groups within the
observation period.
The disease-speciﬁc, self-reported modiﬁed KS [19] was used
to measure knee pain and physical function, because it has been
found to be responsive to change [20]. Pain score (0–50 points)
and function score (0–100 points) are presented separately; clini-
cal dimensions (range of motion, stability, ﬂexion contracture,
extension lag, and alignment) could not be measured in a
patient’s self-administered questionnaire, and thus the total score
could not be derived.
The use of DSM during the week preceding every measure-
ment point was measured based on self-report. The unit costs of
medication per tablet were obtained from CD-Pharmacy [21].
The costs of medication during the waiting period were calcu-
lated as a product of the weeks spent on the waiting list and the
medication costs per week. The calculations for medication costs
were made at each of the four measurement points.
Statistical Analysis
The sample size estimate was based on the primary outcome
variable 15D. A total subgroup of 177 patients would provide
the 80% power (two-tailed a error 5%) to detect clinically
important differences >|0.03| in the 15D score between the ran-
domized groups.
Primary analyses were conducted with an intention-to-treat
(ITT) principle [22], so that patients were followed in the
groups to which they were randomly allocated. When compar-
ing the mean scores of 15D, knee pain, function, and costs of
DSM at the various points of follow-up between SWT and
NFWT, a general linear model (GLM) for repeated measures as
tests of between-subject effects was used. P < 0.05 was consid-
ered statistically signiﬁcant. Also, the mean differences, SDs,
and conﬁdence intervals (CIs) of 95% of the variables 15D,
knee pain and function, WT, and costs of DSM were presented
for the estimated effect.
Baseline characteristics of the randomized groups and the
patients who were lost to follow-up were compared using either
the independent sample t test or chi-square test, depending on
whether the variable was on a continuous or nominal scale.
Missing values on the 15D were replaced if a minimum of
80% of dimensions had been completed, using a regression
model with the patient’s responses for other dimensions, age, and
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sex as explanatory variables [14]. Data analyses were performed
using SPSS for Windows v.14 and v.16 (Chicago, IL).
Results
Of the 555 eligible patients invited to participate in the study,
117 patients (90 women) with a mean age of 71 refused to
participate and were excluded. Thus, 438 patients after provid-
ing a signed informed consent were randomly allocated to either
the SWT (n = 172) or NFWT (n = 266) group. Of these patients,
13 did not return the questionnaire at baseline, although they
had signed informed consent. During the WT, 95 patients were
lost to follow-up, 3 exited the queue, 8 had severe comorbidities,
4 were operated on in a private hospital, 29 had canceled opera-
tions, 4 died while waiting, and 45 did not return the question-
naire at admission. Primary ITT analyses are based on 330
(77%) patients (237 women) with a mean (SD) age of 68
(9.9) years, of which 132 were in the SWT and 198 in the
NFWT group, and the ﬁnal GLM repeated analyses are based on
289 patients, who completed all four questionnaires. Of them,
119 were in the SWT and 170 in the NFWT (Fig. 1).
Baseline Characteristics
The baseline characteristics of the groups were similar (Table 1).
The mean (SD) 15D score in the SWT group was 0.772
Allocated to Short WT group 
 (n=172) 
Completed baseline measurement 
 (n=166) 
Allocated to Nonfixed WT group (n=266) 
Completed baseline measurement (n=259) 
Completed admission measurement  
(n= 132) 
Lost to follow-up at (n= 34) 
   Surgery was canceled (n=6) 
   Died (n=1) 
   Comorbidities (n=5) 
   Unknown reasons (n= 22) 
Completed admission measurement 
(n=198) 
Lost to follow-up (n= 61) 
   Surgery was canceled (n=15) 
   Exited the queue (n=3) 
   Died (n=3) 
   Comorbidities (n=3) 
   Operated in a private hospital (n=4) 
   Unknown reasons (n= 33) 
Randomized (n=438) 
Invited to participate (n=555) 
Excluded (n=117) 
  Refused (n=104) 
  Operated on the contralat. 
  side (n=2) 
  Did not understand Finnish    
  or Swedish (n=2) 
  Inmate of an institution   
  (n=1) 
  Other reasons (n=8) 
Completed all four measurements 
(n= 119) 
  Lost to follow-up (n=13) 
  Unknown reasons 
Completed all four measurements 
(n=170) 
  Lost to follow-up (n=28) 
  Unknown reasons 
In final analyses (n= 119) In final analyses (n=170) 
Figure 1 Patients ﬂow through the trial.
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(0.108) and 0.779 (0.119) in the NFWT group; the difference
was not statistically signiﬁcant or clinically important
(P = 0.539). The mean (SD) pain score was 19.9 (11.8) and
20.9 (12.4) in the SWT and NFWT groups, respectively
(P = 0.355). The percentage of patients receiving DSM was 87%
(n = 118) in the SWT and 88% (n = 181) in the NFWT group.
The mean weekly medication costs were €5.7 and €5.9 in the
SWT and NFWT groups, respectively. The difference was not
statistically signiﬁcant (Table 1).
A comparison between patients who completed the question-
naire and those who were lost to follow-up showed a statistically
signiﬁcant difference in pain score (P = 0.030) (Table 1).
Outcomes andWT
At admission, there was a statistically signiﬁcant difference in
mean WT between the groups: 95 (81) days in the SWT and
239 (135) days in the NFWT group (F value 100.6; 95% CI
116, 99–172, 22; P < 0.001). There was a statistically signiﬁcant
difference between the groups in the weekly costs of DMS, at
€5.33 and €3.57, respectively (F value 4.85; 95%CI 3.54–5.10;
P = 0.029). There were no differences between the randomized
groups in the mean 15D, pain, and function score, and in the
costs of DSM during the WT (Table 2).
Outcomes after TKR
The use and costs of medication had decreased in both groups at
3 months and 1 year after the TKR. In the SWT group, the
weekly costs at 3 months were €3.14 and in the NFWT group
€3.10, and after 1 year they were €1.74 and €2.96, respectively
(Table 3). In repeated measures analyses, the differences were
statistically signiﬁcant between measurement points (F = 13.17;
P < 0.001), but not between the randomized groups (F = 1.17;
P = 0.317) (Table 4).
At 3 months, the mean 15D score was 0.813 in the SWT and
0.837 in the NFWT group, and at 1 year they were 0.813 and
0.852, respectively. The difference between the randomized
groups was statistically signiﬁcant (P = 0.012) after 1 year post-
operatively. The mean pain scores were at 3 months 32.7 and
34.1, respectively, and at 1 year they were 36.3 and 36.9, respec-
tively. The mean function scores were at 3 months 62.78 and
63.8 in the SWT and NFWT respectively, and at 1 year 73.5 and
74.6, respectively. The differences between the randomized
groups were not statistically signiﬁcant (Table 3). There were
statistically signiﬁcant differences between the measurement
points (Table 4).
There were improvements from admission to 12 months post-
operatively in the mean 15D score, and pain and function scores,
and a decrease in the cost of medication in both groups. Assum-
ing that the ﬁnal mean HRQoL score in the SWT group would
carry forward until the ﬁnal measurement point in the NFWT
group, the latter group would gain 0.033 QALYs more than the
SWT group during the whole observation period of almost 700
days (the sum of two areas between the curves in Fig. 2), even if
the SWT group would gain 0.012 QALYs more in the short run
by reaching a better level of HRQoL earlier (the ﬁrst area
Table 1 Characteristics at baseline in patients waiting for total knee replacement and those lost to follow-up
Characteristics
SWT NFWT Lost to follow-up
P value† P value‡n = 132 n = 198 n = 95
Age, mean SD 67 9.5 68 8.9 69 9.3 0.208 0.619
Sex (female), (n [%]) 98 (70) 139 (69) 64 (66) 0.308 0.294
Living alone (n [%]) 50 (32) 65 (37) 33 (38) 0.180 0.900
Professional education (n [%]) 31 (23) 38 (19) 11 (13) 0.218 0.168
Employment status
Retired (n [%]) 107 (81) 169 (85) 71 (83) 0.050 0.834
Comorbidity (n [%]) 102 (77) 154 (78) 70 (81) 0.509 0.566
Medication to arthritis (n [%]) 115 (87) 175 (88) 71 (82) 0.428 0.208
Cost of medication €/week 5.72 7.2 5.91 6.1 4.89 6.2 0.803 0.456
Body mass index (kg/m2) 29.4 7.0 29.4 4.4 28.55 7.1 0.121 0.43
Pain score, mean SD§ 19.9 11.8 20.92 12.4 19.96 11.0 0.355 0.030*
Function score, mean SD|| 48.42 22.1 46.95 23.3 52.38 22.6 0.567 0.171
15D score, mean SD¶ 0.772 0.108 0.779 0.119 0.779 0.11 0.539 0.835
*P < 0.05.
†Differences between the randomized groups.
‡Differences between the patients who completed the questionnaire and those lost to follow-up.
§The scale 0–50, worst to best.
||The scale 0–100, worst to best.
¶The scale 0–1, worst to best.









15D score 0.768 (0.15) 0.779 (0.10) -0.020 to 0.029 0.031 0.744
Pain score 18.93 (11.8) 22.79 (12.40) -1.478 to 3.969 0.308 0.369
Function score 48.42 (22.1) 46.95 (23.31) -6.659 to 3.493 0.737 0.540
Cost of medication €/week 5.33 (7.55) 3.57 (5.38) 3.54 to 5.10 4.85 0.029†
Cost of medication €/waiting time (WT) 89.19 (199.19) 120.54 (194.82) 80.75 to 131.09 1.50 0.222
WT (days) 94.60 (81.3) 239.2 (135.1) 154.5 to 188.09 100.60 0.000‡
*Number of observations varies because of missing values.
†P < 0.05, ‡P < 0.001.
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between the curves in Fig. 2), although those in the NFWT had
better quality of life postoperatively.
Interpretation
Scientiﬁc evidence on the relationship between WT and TKR
outcomes is inconsistent, while the absence of randomized trials
has prevented an assessment of whether longer waiting is
somehow related to health and quality-of-life outcomes. To our
knowledge, the present study is the ﬁrst to assess the use and
costs of DSM in TKR patients randomly allocated to SWT and
NFWT groups. The study also analyzed whether the length of the
WT was related to HRQoL, knee pain, and function as measured
by the 15D and modiﬁed KS, respectively.
The main ﬁnding was that overall, there was no difference in
HRQoL between the WT groups in different measurement
points. Nevertheless, those in the NFWT group reached a higher
level of HRQoL postoperatively and consequently gained 0.033
QALYs more than the SWT group during the whole observation
period of almost 700 days. Those in the SWT group had a worse
pain score at baseline, which reﬂected in an increased use of DSM
during the waiting period. The weekly costs were almost identi-
cal in both groups at each of the three measurement points. The
same applies to the mean pain and function scores, which
reached their highest values 12 months postoperatively.
In this study, the patients’ HRQoL at baseline was deterio-
rated. In fact, it seems to be worse than in two earlier studies,
where the mean scores before operation measured by the 15D
were 0.83 [23] and 0.81 [24] compared to our 0.77 to 0.78. The
patients had pain and difﬁculties in functioning. Nevertheless, in
an earlier study among these patients, it was found that they used
very little health and social services during the WT with no
statistically signiﬁcant difference between the randomized groups
[25]. The length of WT alone did not affect HRQoL or pain and
function scores, which is in line with the ﬁndings of some earlier
studies [7,8,19]. TKR has been found to be effective [24,26,27],
and this study also showed a signiﬁcant improvement in HRQoL,




interval (CI) for mean P value
One year
postoperatively 95% CI
for mean P valueSWT NFWT SWT NFWT
15D score, mean 0.813 0.837 -0.002 to 0.05 0.06 0.813 0.852 0.01 to 0.07 0.012*
SD 0.12 0.11 0.14 0.1
Pain score, mean 32.7 34.07 -1.55 to 4.85 0.311 36.27 36.95 -3.11 to 4.47 0.724
SD 13.03 13.49 13.15 12.83
Function score, mean 62.78 63.86 -7.12 to 4.96 0.725 73.5 74.63 -4.71 to 6.98 0.703
SD 25.58 25.22 23.32 22.28
Costs of medication, mean (€/week) 3.14 3.1 -1.48 to 1.20 0.838 1.74 2.96 -0.36 to 2.25 0.142
SD 5.88 7.29 3.96 4.07
*P < 0.05.
Table 4 Waiting time effect between the randomized groups
Outcome Source F value P value
15D Time 38.746 0.000†
Time* 15D 1.66 0.177*
Pain score Time 159.686 0.000†
Time* pain score 0.645 0.563*
Function score Time 118.47 0.000†
Time* function score 1.102 0.346*
Costs of medication Time 13.172 0.000†
Time* costs of medication 1.17 0.317*
*Difference between randomized groups.
†Difference between the measurement points.
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Figure 2 The quality-adjusted life-year gain
(areas between the curves).
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and in pain and function 3 and 12 months postoperatively in
both randomized groups.
To our knowledge, no studies have so far been published on
the effect of WT on the use and costs of DSM after the TKR.
Earlier prospective studies on the costs and outcomes of the WT
for TKR have found that waiting more than 6 months was
associated with higher total costs and deterioration in physical
function while waiting [28,29]. These cost results are not com-
parable to ours, as they estimated all costs during the waiting
period. Nunez et al. (2007) ﬁndings on HRQoL and weekly
medication costs in patients with OA on a waiting list for TKR
were in line with ours.
Strengths and Limitations
The strengths of this study were that the patients awaiting THR
were prospectively followed from the time of being placed on the
waiting list to admission—with WTs recorded precisely—and
further for a year of follow-up postoperatively, providing evi-
dence of the effect of WT on pre- and postoperative health status.
Further, the patients were randomly assigned to either the SWT
or NFWT group, the randomization was successfully completed,
and the groups did not differ from each other at baseline. The
ﬁndings were based on the simultaneous use of patient-reported
generic and disease-speciﬁc outcome instruments. The results,
based on ITT analyses, indicated that there were no statistically
signiﬁcant differences in health outcomes between the random-
ized groups during the WT. This was also tested with repeated
measures analyses. The within-subject test indicated that there
was a signiﬁcant time effect (i.e., the outcomes did change over
time), but an insigniﬁcant interaction effect (i.e., there was no
difference between the groups).
Some limitations pertain to this study. First, the patients who
refused to participate in the study were older, and second, a total
of 29 patients in the SWT group waited more than 3 months. The
reasons were hospitals’ limited capacity to carry out TKR within
the 3 months WT period or the patient’s unwillingness to have
TKR within 3 months, or they were too tired to complete the
questionnaires. Because of these factors, the differences between
the randomized groups may have been underestimated. Never-
theless, the primary analysis was based on the ITT principle to
address the question of clinical effectiveness and to avoid the bias
associated with a nonrandom loss of participants.
Third, although SF-36 has been widely used in OA area, we
chose to use the 15D. SF-36 is basically a proﬁle instrument and
does not thus belong to the category of instruments producing a
valuation-based single index number. Nevertheless, in 1998, the
ﬁrst algorithm was published to generate a valuation-based single
index score, SF-6D score, from the SF-36. Hawthorne et al. [16]
showed that the 15D performed at least as well as the SF-6D.
Since a new algorithm has been devised for the SF-6D in 2002
[30]. Recent research with that algorithm indicates that espe-
cially in the rehabilitation of musculoskeletal disorder, the 15D
was at least as responsive as the SF-6D [18].
Further, we looked at medication cost only, and medication
information was obtained only from patient self-reports, while
there was no distinction between self-care and prescription medi-
cation. For temporary medication, we used mean dosages. A
study is ongoing, where the effect of WTs on the total cost of hip
and knee replacements is being investigated.
Conclusion
In Finland, the so-called treatment guarantee was introduced in
2005 with a maximum WT of less than 6 months [31]. Since
then, there has been discussion in health-care policy about the
optimal and effective WT in elective surgery. When considering
the optimal timing, information is needed on the effect of WT on
key parameters. This study showed that the length of the WT, at
least as realized in practice in this study, did not result in different
health outcomes in the randomized groups in three cross-
sectional follow-up measurements from baseline to 1 year post-
operatively. Those in the SWT group reached better HRQoL 3
months earlier than those in the NFWT group, but the latter had
better HRQoL after the operation and gained more QALYs
overall during the study period. To be useful for future policy
work, further research is needed to determine the optimal timing.
Source of ﬁnancial support: This study was ﬁnancially supported by the
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Hospital, HUS HUCH Surgical Hospital, Orton Orthopaedic Hospital,
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